Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 1 min 19 sec ago

American Shared Hospital Services Announces Proposed 2016 CMS Gamma Knife and Proton Therapy Reimbursement Rates

Mon, 07/27/2015 - 15:29
SAN FRANCISCO--(Healthcare Sales & Marketing Network)--AMERICAN SHARED HOSPITAL SERVICES (NYSE MKT:AMS), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, announced today that the Centers for Medi...
Devices, Oncology, Reimbursement
American Shared Hospital Services, Gamma Knife, proton therapy, radiosurgery

Varian Signs Contracts to Equip Two National Proton Therapy Centers in England

Mon, 07/27/2015 - 15:26
CRAWLEY, England, July 27, 2015 -- (Healthcare Sales & Marketing Network) -- Varian Medical Systems UK Ltd announced today it had signed contracts with the National Health Service to equip and service two new national NHS proton therapy centers in England...
Devices, Oncology
Varian Medical Systems, ProBeam, proton therapy, radiotherapy

Castle Biosciences Closes $11.7 Million Tranche of $20 Million Financing

Mon, 07/27/2015 - 15:24
Led by investor Industry Ventures to support growth in adoption of cutaneous melanoma diagnostic test FRIENDSWOOD, Texas--(Healthcare Sales & Marketing Network)--Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment d...
Diagnostics, Oncology, Venture Capital
Castle Biosciences, DecisionDx

Oncobiologics Secures $31 Million Financing to Advance BioSymphony(TM) Platform Development and Monoclonal Antibody Biosimilars Pipeline

Mon, 07/27/2015 - 15:20
CRANBURY, N.J., July 27, 2015 -- (Healthcare Sales & Marketing Network) -- Oncobiologics, Inc., announced the closing of a $31 million financing. Proceeds will be used to support continued development and expansion of the company's proprietary BioSymphon...
Biopharmaceuticals, Venture Capital
Oncobiologics, biosimilar, BioSymphony

POZEN Appoints Scott Charles Senior Vice President of Finance

Mon, 07/27/2015 - 15:16
Charles to Serve as Chief Financial Officer of Aralez Following Completion of Merger with Tribute Pharmaceuticals CHAPEL HILL, N.C.--(Healthcare Sales & Marketing Network)--POZEN Inc. (“POZEN”) (POZN), a pharmaceutical company committed to developin...
Biopharmaceuticals, Personnel
POZEN

European Medicines Agency Validates and Grants Accelerated Assessment of Marketing Authorization Application for Empliciti (elotuzumab) For the Treatment of Multiple Myeloma in Patients Who Have Received One or More Prior Therapies

Mon, 07/27/2015 - 15:14
Results from two clinical trials (ELOQUENT-2 & CA204-009), each combining Empliciti with a different standard of care regimen included in the submission Empliciti is poised to be the first-in-class SLAMF7-directed immunostimulatory antibody PRINCETO...
Biopharmaceuticals, Oncology, Regulatory
Bristol-Myers Squibb, AbbVie, Empliciti, elotuzumab, multiple myeloma

FDA approves Novartis drug Odomzo(R) (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer

Fri, 07/24/2015 - 22:34
Approval is based on pivotal Phase II study in which objective response rate (ORR) in patients with laBCC was 58%; responses were durable(1) Basal cell carcinoma, the most common form of skin cancer, can be highly disfiguring at advanced stages(2) Od...
Biopharmaceuticals, Oncology, FDA
Novartis, Odomzo, sonidegib, basal cell carcinoma

Regeneron and Sanofi Announce FDA Approval of Praluent(R) (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., for the Treatment of High LDL Cholesterol in Adult Patients

Fri, 07/24/2015 - 19:49
Praluent available early next week to U.S. patients Companies to host Investor Conference Call on Praluent today at 15:30 EDT/21:30 CET TARRYTOWN, N.Y. and PARIS, July 24, 2015 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, ...
Biopharmaceuticals, Cardiology, FDA
Regeneron Pharmaceuticals, Sanofi, Praluent, alirocumab, PCSK9

AcelRx Announces Positive CHMP Opinion for Zalviso in the Management of Acute Moderate-to-Severe Post-Operative Pain in Adult Patients

Fri, 07/24/2015 - 14:03
REDWOOD CITY, Calif., July 24, 2015 -- (Healthcare Sales & Marketing Network) -- AcelRx Pharmaceuticals, Inc. (ACRX), (AcelRx) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopt...
Biopharmaceuticals, Drug Delivery, Regulatory
AcelRx Pharmaceuticals, Zalviso, sufentanil, sublingual tablet

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent(R) (alirocumab) for the Treatment of Hypercholesterolemia

Fri, 07/24/2015 - 13:53
TARRYTOWN, N.Y. and PARIS, July 24, 2015 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today announced that the European Medicine Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has a...
Biopharmaceuticals, Regulatory
Regeneron Pharmaceuticals, Sanofi, Praluent, alirocumab, hypercholesterolemia

St. Jude Medical and Thoratec Announce Definitive Agreement

Thu, 07/23/2015 - 18:05
Combination Accelerates Innovation-Based Growth Program and Expands Heart Failure Franchise ST. PAUL, Minn. & PLEASANTON, Calif.--(Healthcare Sales & Marketing Network)--St. Jude Medical (STJ) and Thoratec (THOR) today announced that the Boards of Direc...
Devices, Cardiology, Mergers & Acquisitions
St. Jude Medical, Thoratec, HeartMate, Ventricular Assist

SutroVax raises $22 million in Series A

Thu, 07/23/2015 - 17:38
Vaccine Spin-off from Sutro Biopharma to Utilize Site-Specific Conjugation Technology SOUTH SAN FRANCISCO, Calif., July 23, 2015 -- (Healthcare Sales & Marketing Network) -- SutroVax, a recently established biopharmaceutical vaccine company, today anno...
Biopharmaceuticals, Venture Capital, Personnel
SutroVax, Xpress CF

RaNA Therapeutics Secures $55 Million in Oversubscribed Series B Financing

Thu, 07/23/2015 - 17:33
Proceeds will Further Strengthen RaNA’s Proprietary Platforms and Advance Lead Optimization and IND-Enabling Studies for Priority Programs CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--RaNA Therapeutics, a leader in the discovery and develop...
Biopharmaceuticals, Venture Capital
RaNA Therapeutics

Dr. Jon K. Hayashida Named Vice President Global Clinical and Medical Affairs for STAAR Surgical

Thu, 07/23/2015 - 15:18
MONROVIA, Calif., July 23, 2015 -- (Healthcare Sales & Marketing Network) -- STAAR Surgical Company (STAA), a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye, has named Dr. Jon K. Hayashida to the newly ...
Devices, Ophthalmology, Personnel
STAAR Surgical, Implantable Collamer Lens

Sunshine Heart Provides Update on COUNTER HF(TM) US Pivotal Study for C-Pulse(R) Heart Assist System

Thu, 07/23/2015 - 15:11
EDEN PRAIRIE, Minn., July 23, 2015 -- (Healthcare Sales & Marketing Network) -- Sunshine Heart, Inc. (SSH) announced today an update on its COUNTER HF(TM) US pivotal study for the C-Pulse Heart Assist System. COUNTER HF is a prospective, randomized, multi-...
Devices, Cardiology
Sunshine Heart, COUNTER HF, C-Pulse system, balloon counterpulsation

GenSight Biologics Closes $36 Million Series B Preferred Stock Financing

Thu, 07/23/2015 - 15:04
PARIS--(Healthcare Sales & Marketing Network)--GenSight Biologics S.A. (GenSight), a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye, and in the future, of the cent...
Biopharmaceuticals, Ophthalmology, Venture Captial
GenSight Biologics, Leber’s Hereditary Optic Neuropathy

Medrobotics(R) Corporation Receives FDA Clearance to Market Flex(R) Robotic System

Thu, 07/23/2015 - 14:57
Company Initiates U.S. Launch of the Flex® Robotic System for Transoral Procedures in the Mouth and Throat RAYNHAM, Mass.--(Healthcare Sales & Marketing Network)--Medrobotics Corp., a surgical robotics company, announced today it has received FDA c...
Devices, Surgery, FDA, Product Launch
Medrobotics, Flex Robotic System, Transoral, robotic surgery

Wilson Therapeutics Announces the Appointment of Dr. Carl Bjartmar as Chief Medical Officer

Wed, 07/22/2015 - 15:13
STOCKHOLM, July 22, 2015 -- (Healthcare Sales & Marketing Network) -- Wilson Therapeutics AB, a privately-held biopharmaceutical company developing novel treatments for patients with Wilson's Disease, today announced the appointment of Dr. Carl Bjartmar a...
Biopharmaceuticals, Personnel
Wilson Therapeutics, Wilson's Disease

Voyager Therapeutics Appoints Michael Higgins to Board of Directors

Wed, 07/22/2015 - 15:12
CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Voyager Therapeutics, Inc., a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced the appointment of Mich...
Biopharmaceuticals, Neurology, Personnel
Voyager Therapeutics, Parkinson’s disease, amyotrophic lateral sclerosis

Second Sight Announces First Age-Related Macular Degeneration Patient Receives the Argus II Retinal Prosthesis System as Part of Groundbreaking Study

Wed, 07/22/2015 - 15:07
Five Patients to be Implanted with the Argus® II to Evaluate the Feasibility of the Device in Patients with Dry Age-Related Macular Degeneration SYLMAR, Calif.--(Healthcare Sales & Marketing Network)--Second Sight Medical Products, Inc. (Nasdaq:EYES...
Devices, Ophthalmology
Second Sight Medical Products, Argus II, Retinal Prosthesis

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong